Napo Pharms Inc Drug Patent Portfolio
Napo Pharms Inc owns 1 orange book drug protected by 5 US patents Given below is the list of Napo Pharms Inc's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8962680 | Methods and compositions for treating HIV-associated diarrhea | 31 Oct, 2031 | Active |
US9585868 | Methods and compositions for treating HIV-associated diarrhea | 31 Oct, 2031 | Active |
US7341744 | Method of treating secretory diarrhea with enteric formulations of proanthocyanidin polymer | 16 Jun, 2018 | Expired |
US7323195 | Enteric formulations of proanthocyanidin polymer antidiarrheal compositions | 07 Jun, 2018 | Expired |
US8574634 | Compositions and methods of treatment with proanthocyanidin polymer antidiarrheal compositions | 11 Jan, 2018 | Expired |
Latest Legal Activities on Napo Pharms Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Napo Pharms Inc.
Activity | Date | Patent Number |
---|---|---|
Expire Patent
Critical
| 13 Dec, 2021 | US8574634 |
Maintenance Fee Reminder Mailed
Critical
| 28 Jun, 2021 | US8574634 |
Payment of Maintenance Fee, 4th Yr, Small Entity | 31 Aug, 2020 | US9585868 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 01 Jul, 2020 | US9585868 |
Email Notification
Critical
| 01 Jul, 2020 | US9585868 |
Correspondence Address Change
Critical
| 29 Jun, 2020 | US9585868 |
Correspondence Address Change
Critical
| 29 Jun, 2020 | US8574634 |
Expire Patent
Critical
| 02 Mar, 2020 | US7323195 |
Maintenance Fee Reminder Mailed
Critical
| 16 Sep, 2019 | US7323195 |
Patent Issue Date Used in PTA Calculation
Critical
| 07 Mar, 2017 | US9585868 |
Recordation of Patent Grant Mailed
Critical
| 07 Mar, 2017 | US9585868 |
Email Notification
Critical
| 16 Feb, 2017 | US9585868 |
Issue Notification Mailed
Critical
| 15 Feb, 2017 | US9585868 |
Application Is Considered Ready for Issue
Critical
| 31 Jan, 2017 | US9585868 |
Dispatch to FDC | 31 Jan, 2017 | US9585868 |
Napo Pharms Inc's Family Patents
Napo Pharms Inc drugs have patent protection in a total of 20 countries. It's US patent count contributes only to 30.0% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Napo Pharms Inc Drug List
Given below is the complete list of Napo Pharms Inc's drugs and the patents protecting them.
1. Mytesi
Mytesi is protected by 5 patents, out of which 3 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8962680 | Methods and compositions for treating HIV-associated diarrhea |
31 Oct, 2031
(7 years from now)
| Active |
US9585868 | Methods and compositions for treating HIV-associated diarrhea |
31 Oct, 2031
(7 years from now)
| Active |
US7341744 | Method of treating secretory diarrhea with enteric formulations of proanthocyanidin polymer |
16 Jun, 2018
(6 years ago)
| Expired |
US7323195 | Enteric formulations of proanthocyanidin polymer antidiarrheal compositions |
07 Jun, 2018
(6 years ago)
| Expired |
US8574634 | Compositions and methods of treatment with proanthocyanidin polymer antidiarrheal compositions |
11 Jan, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mytesi's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List